TNAX Biopharma is a venture-backed biopharmaceutical company focused on the development of novel antibody therapeutics for unmet medical needs of patients with intractable diseases.  Our scientific co-founder, Dr. Akira Shibuya, a professor at University of Tsukuba, is a well-known scientist, who discovered unique immunoreceptors and their ligands.  He showed that these molecules play important roles in immunity and inflammation. (>Lab Link)

We believe that these immunoreceptors and their ligands would be potential targets for a new class of therapeutics.  TNAX Biopharma conducts joint research with the University of Tsukuba and leverages intellectual property rights licensed from the university. The company provides truly valuable therapeutics to patients around the world and contributes to society through drug discovery innovation and partnering.